# US 2019/0316138 A1 · Oligonucleotide compositions with enhanced efficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316138 A1
- Document ID: US20190316138A1
- Status: Published application
- Kind: A1
- Application number: 16/253,180
- Filed: 2019-01-21
- Published: 2019-10-17
- Earliest claimed: 2002-02-01
- Assignees: Life Technologies Corporation
- Applicants: Life Technologies Corporation
- Inventors: Tod Woolf; Margaret Taylor
- Web page: https://patentgrep.com/patent/US20190316138A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12Y 207/11022: Cyclin-dependent kinase (2.7.11.22)
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- C12N 2310/11: Antisense
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/30: Special therapeutic applications
- C12N 2320/31: Combination therapy
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2330/30: chemically synthesised
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.

## Claims

### Claim at position 1

-33. (canceled)

### Claim 34

A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of three or more different double-stranded oligonucleotides in equimolar concentrations,
wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,
each double-stranded oligonucleotide consists of two separate strands,
each strand is between 15 and 40 nucleomonomers in length;
wherein the combination is capable of RNA interference (RNAi).

### Claim 35 (depends on 34)

The composition of claim 34 wherein each strand is between 20 and 30 nucleomonomers in length.

### Claim 36 (depends on 34)

The composition of claim 34 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

### Claim 37 (depends on 34)

The composition of claim 34 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

### Claim 38 (depends on 34)

The composition of claim 34 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

### Claim 39 (depends on 34)

The composition of claim 34, wherein the target gene is a mammalian gene.

### Claim 40

A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of two different double-stranded oligonucleotides in equimolar concentrations,
wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,
each double-stranded oligonucleotide consists of two separate strands,
each strand is between 15 and 40 nucleomonomers in length,
wherein the combination is capable of RNA interference (RNAi).

### Claim 41 (depends on 40)

The composition of claim 40 wherein each strand is between 20 and 30 nucleomonomers in length.

### Claim 42 (depends on 40)

The composition of claim 40 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

### Claim 43 (depends on 40)

The composition of claim 40 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

### Claim 44 (depends on 40)

The composition of claim 40 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

### Claim 45 (depends on 40)

The composition of claim 40, wherein the target gene is a mammalian gene.

### Claim 46

A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of three, four, five, six, seven or eight different double-stranded oligonucleotides in equimolar concentration,
wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,
each double-stranded oligonucleotide consists of two separate strands,
each strand is between 15 and 40 nucleomonomers in length,
wherein the combination is capable of RNA interference (RNAi).

### Claim 47 (depends on 46)

The composition of claim 46 wherein each strand is between 20 and 30 nucleomonomers in length.

### Claim 48 (depends on 46)

The composition of claim 46 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

### Claim 49 (depends on 46)

The composition of claim 46 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

### Claim 50 (depends on 46)

The composition of claim 46 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

### Claim 51 (depends on 46)

The composition of claim 46 wherein the combination of double-stranded oligonucleotides consists of three or four different double-stranded oligonucleotides in equimolar concentration.

### Claim 52 (depends on 51)

The composition of claim 51 wherein the combination of double-stranded oligonucleotides consists of four different double-stranded oligonucleotides in equimolar concentration.

### Claim 53 (depends on 34)

A method of inhibiting protein synthesis in a cell comprising
contacting the cell with the composition of claim 34 thereby inhibiting the synthesis of a target protein.

### Claim 54 (depends on 40)

A method of inhibiting protein synthesis in a cell comprising
contacting the cell with the composition of claim 40 thereby inhibiting the synthesis of a target protein.

### Claim 55 (depends on 46)

A method of inhibiting protein synthesis in a cell comprising
contacting the cell with the composition of claim 46 thereby inhibiting the synthesis of a target protein.
